Evidence map›Paper›PMID 25590316›Full record

ReviewAmerican journal of rhinology & allergy

Factors driving the aspirin exacerbated respiratory disease phenotype.

John W Steinke, Larry Borish

Abstract readReview
In one paragraph

Review in American journal of rhinology & allergy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 50 citations in OpenAlex.

  1. Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Suppression of aspirin-mediated eosinophil activation by prostaglandin EAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2019
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Samter's Triad: State of the Art.Clinical and experimental otorhinolaryngology · 2018
    Review
  17. Review
  18. Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2017
    Article
  19. Article
  20. Genetic and Epigenetic Components of Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

John W SteinkeAsthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA.
Larry Borish
Carter Center · USUniversity of Virginia Health System · US

Funding

Viruses and IgE in relation to mechanisms of asthmaP01AI050989 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI PLATTS-MILLS, THOMAS A. · 2001 to 2005
$4.9M
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils iR01AI057438 · NIAID · UNIVERSITY OF VIRGINIA · PI BORISH, LARRY C · 2006 to 2015
$3.7M
RECOMBINANT HUMAN INTERLEUKIN-4 RECEPTOR IN ASTHMAR01AI047737 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI BORISH, LARRY C · 2000 to 2004
$1.3M
NIAID NIH HHS P01 AI050989NIAID NIH HHS P01 AI50989NIAID NIH HHS R01 AI047737NIAID NIH HHS R01 AI057438NIAID NIH HHS R01 AI47737
6 · The paper itself

Abstract

backgroundAspirin-exacerbated respiratory disease (AERD) is explained in part by overexpression of 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes (CysLTs) and driving the surge in CysLT production that occurs with aspirin ingestion. Similarly, AERD is characterized by the overexpression of CysLT receptors. Increased levels of both interleukin (IL)-4 and interferon (IFN)-γ are present in the tissue of AERD subjects. Previous studies demonstrated that IL-4 is primarily responsible for the up-regulation of LTC4S by mast cells.

methodsLiterature review.

resultsOur previous studies demonstrated that IFN-γ, but not IL-4, drives this process in eosinophils. These published studies also extend to both IL-4 and IFN-γ the ability to up-regulate CysLT receptors. Prostaglandin E2 (PGE2) acts to prevent CysLT secretion by inhibiting mast cell and eosinophil activation. PGE2 concentrations are reduced in AERD, and our published studies confirm that this reflects diminished expression of cyclooxygenase (COX)-2. A process again that is driven by IL-4. Thus, IL-4 and IFN-γ together play an important pathogenic role in generating the phenotype of AERD. Finally, induction of LTC4S and CysLT1 receptors by IL-4 reflects in part the IL-4-mediated activation of signal transducer and activator of transcription 6 (STAT6). Our previous studies demonstrated that aspirin blocks trafficking of STAT6 into the nucleus and thereby prevents IL-4-mediated induction of these transcripts, thereby suggesting a modality by which aspirin desensitization could provide therapeutic benefit for AERD patients.

conclusionThis review will examine the evidence supporting this model.

Indexed as

AspirinCysteineEosinophiliaHumansInterferon-gammaInterleukin-4Leukotriene E4LeukotrienesMast CellsPhenotypeReceptors, LeukotrieneReceptors, Prostaglandin ERespiratory Tract DiseasesAspirinCysteinecysteinyl-leukotrieneInterferon-gammaInterleukin-4leukotriene D4 receptorLeukotriene E4LeukotrienesReceptors, LeukotrieneReceptors, Prostaglandin E

Identifiers

PMID25590316
PMCPMC4288232
OpenAlexW2322202289

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.